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Abstract Vesicoureteral reflux (VUR) is the most common
uropathy affecting children. Compared to children without
VUR, those with VUR have a higher rate of pyelonephritis
and renal scarring following urinary tract infection (UTI).
Options for treatment include observation with or without
antibiotic prophylaxis and surgical repair. Surgical inter-
vention may be necessary in patients with persistent reflux,
renal scarring, and recurrent or breakthrough febrile UTI.
Both open and endoscopic approaches to reflux correction
are successful and reduce the occurrence of febrile UTI.
Estimated success rates of open and endoscopic reflux
correction are 98.1% (95% CI 95.1, 99.1) and 83.0% (95%
CI 69.1, 91.4), respectively. Factors that affect the success
of endoscopic injection include pre-operative reflux grade
and presence of functional or anatomic bladder abnormal-
ities including voiding dysfunction and duplicated collect-
ing systems. Few studies have evaluated the long-term
outcomes of endoscopic injection, and with variable results.
In patients treated endoscopically, recurrent febrile UTI
occurred in 0–21%, new renal damage in 9–12%, and
recurrent reflux in 17–47.6% of treated ureters with at least
1 year follow-up. These studies highlight the need for
standardized outcome reporting and longer follow-up after
endoscopic treatment.
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Abbreviations
VUR Vesicoureteral reflux
DX/HA = DHA Dextranomer/hyaluronic acid
UTI Urinary tract infection
UGS Urogenital sinus
UVJ Ureterovesical junction
VCUG Voiding cystourethrography
RNC Radionuclide cystogram
PTFE Polytetrafluoroethylene
STING Subureteric Teflon injection
HIT Hydrodistention implantation technique
DMSA
99mTechnetium-dimercaptosuccinic acid
AUA American Urological Association
CAP Continuous antibiotic prophylaxis
Introduction/Background
Vesicoureteral reflux (VUR) represents the retrograde flow
of urine from the bladder to the upper urinary tract. The true
prevalence of VUR is unknown, as many children are
asymptomatic. The prevalence of VUR in normal children
has been estimated to be 0.4–1.8% [1]. The prevalence of
VUR is significantly higher in siblings of patients with
VUR (46%), children with urinary tract infection (UTI)
(30%), infants with prenatal hydronephrosis (16%), and in
the presence of urogenital anomalies such as posterior
urethral valves (PUV) (60%), cloaca (60%), and duplex
kidney (46%) [2–4].
Embryology/Pathogenesis
Primary VUR may be due to either abnormal position or
integrity of the ureterovesical junction (UVJ). The ureter
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mesonephric or Wolffian duct during the fifth week of
gestation. The distal end of the bud ultimately becomes
incorporated into the part of the urogenital sinus (UGS)
that becomes the trigone. Contrary to previous thought, a
recent study of recombinant murine models showed that
the trigone derives predominantly from bladder smooth
muscle with minor contribution from ureteral smooth
muscle [5]. The intramural portion of the ureter is
passively compressed by the bladder wall during filling,
thus preventing retrograde flow of urine. According to the
Mackie-Stephens ureteral bud theory, ectopic ureteral
budding leads to an ectopic ureteral orifice [6, 7]. A
ureteral bud that arises low or caudal from the mesoneph-
ric duct results in superolateral displacement of the
ureteral orifice, insufficient length of the intravesical
submucosal ureter, and reflux. Dissections of the UVJ in
non-refluxing children demonstrated an approximate tun-
nel length to ureteral diameterr a t i oo f5 : 1v e r s u st o1 . 4 : 1
in refluxing UVJs [8]. Interactions of the ureteral bud and
well-differentiated metanephric blastema are critical to
normal kidney formation. Ectopic budding may lead to
interactions with poorly differentiated portions of the
metanephros, resulting in renal malformations as dyspla-
sia, hypoplasia, or agenesis, collectively referred to as
congenital reflux nephropathy.
Evaluation/Grading
Voiding cystourethrography (VCUG) is the gold standard
for diagnosis of reflux. This is a fluoroscopic study in
which the bladder is gravity-filled with contrast using a
urethral catheter. A VCUG can be performed following
clinical or culture evidence that an active urinary infection
has been adequately treated. The radionuclide cystogram
(RNC) may also be used to detect reflux with the advantage
of reduced radiation exposure. However, this study provides
less anatomic detail (e.g., does not show calyceal architecture
or detect posterior urethral valves) compared to the standard
VCUG and should not be performed for initial evaluation of
males. Inour experience, RNC has been used inthe follow-up
evaluation of patients diagnosed with reflux.
Medical evaluation of children with reflux should
include measurement of height, weight, blood pressure,
urinalysis for proteinuria and bacteruria, and serum creat-
inine in the presence of bilateral cortical abnormalities [9].
A grading system for reflux was established by the
International Reflux Study Committee established in 1981
to aid with clinical management and prognostication. Five
grades are defined based on the extent of reflux and degree
of dilation of the upper tract on imaging [10, 11] (Fig. 1).
Natural history
Spontaneous resolution of primary reflux is common. This is
thought to be multi-factorial, due in part to remodeling of the
UVJ, elongation of the intravesical ureter, and stabilization of
bladder voiding dynamicsover time.Atbirth, thelikelihoodof
spontaneous resolution is inversely proportional to the initial
grade of reflux; approximately 80% of low-grade (I and II)
reflux will resolve spontaneously vs. about 50% of grade III
reflux. Few or approximately 20% of high-grade (IV and V)
refluxwillresolve[12]. For older children, resolution depends
on both initial grade of reflux, gender, and age at initial
diagnosis [13]. Other factors that affect reflux resolution
include voiding dysfunction, presence of renal scarring, and
occurrence of reflux during bladder filling or emptying. In
general, reflux is more likely to resolve in younger patients
with low-grade reflux and normal renal ultrasound.
Rationale/Indications for surgical management
Decisions for surgical repair are individualized and based on
patient age, health, reflux grade, clinical course, compliance,
renal scarring, and parental preference. Prevention of febrile
UTI or pyelonephritis is one of the primary goals of surgical
management. Surgical cureof VUR reduces the occurrence of
pyelonephritis, though it has not been proven to reduce renal
injury. Patients with recurrent pyelonephritis and/or persistent
reflux benefit most from surgery [14].
A systematic review of 33 studies evaluating
99mtechnetium-
dimercaptosuccinic acid (DMSA) scan abnormalities in
children with initial UTI demonstrated that 57% of
children had changes consistent with acute pyelonephritis
on acute-phase DMSA scan and 15% had renal scarring
o nf o l l o w - u pD M S As c a n[ 15]. Approximately 25% of
children with a first UTI had VUR and were significantly
more likely to develop both pyelonephritis (RR 1.5 [95%
CI: 1.1-1.9]) and renal scarring (RR 2.6 [95% CI: 1.7-
3.9]), compared to children without VUR [15].
Recommendations for treatment were published by the
pediatric VUR guidelines panel of the American Urological
Association (AUA) in 1997 [16]. Factors included in these
recommendations were patient age at presentation, grade of
reflux, unilateral vs. bilateral reflux, persistent reflux on
follow-up, and presence or absence of renal scarring. In
general, surgical intervention was recommended in patients
who were older at initial presentation, and had dilating,
bilateral, or persistent reflux, and renal scarring. Following
FDA approval of Deflux® as a bulking agent for the
treatment of VUR grades 1–4, the 2010 AUA guidelines
were revised to include endoscopic treatment of reflux for
patients with febrile break-through UTI [1].
552 Pediatr Nephrol (2012) 27:551–561Relative indications for surgical correction:
– High-grade reflux
– Low probability of spontaneous resolution [17]
– Renal scarring
– Recurrent pyelonephritis
– Breakthrough febrile UTI while on continuous antibiotic
prophylaxis
– Parental preference
Surgical treatment of VUR
Options for surgical repair of VUR include open, laparo-
scopic, and endoscopic techniques.
Open repair
Open repairs prevent reflux by increasing the length of the
intravesical ureter, facilitating compression of the ureter
against the detrusor muscle during bladder filling (Table 1).
These procedures generally require inpatient hospitalization
for management of post-operative pain as well as temporary
urinary catheter drainage. In contrast, endoscopic repair is
an outpatient procedure with minimal post-operative pain
and no need for urinary catheter. The reduced morbidity of
endoscopic repair, however, may come at the cost of
decreased surgical success.
The estimated success rate of open surgery is 98.1% (95%
CI 95.1, 99.1) [1] .P r o s p e c t i v er a n d o m i z e dc o n t r o l l e ds t u d i e s
comparing open surgical correction of VUR and continuous
antibiotic prophylaxis (CAP) have shown a reduction in the
occurrence of febrile UTIs, but no difference in the rates of
renal scarring. Ten-year results of the International Reflux
Study in Children demonstrated recurrent febrile UTI in 14%
of patients treated with open surgical repair versus 25%
treated with antibiotic prophylaxis [18]. There was no
difference in the incidence of new renal scar following
antibiotic treatment (6-12%) or open surgical repair (5-14%)
[18–20]. Complications of open surgical repair include
obstruction (2%) and contralateral reflux (9%) [16].
Various open approaches have been described including
extravesical, intravesical, as well as combined approaches.
In 1952, Hutch initially described the technique of
elongating the intravesical ureter to create an anti-reflux
valve in paraplegic patients with VUR [21]. Since then,
multiple additional techniques have been described.
Extravesical
Lich-Gregoir (1961, 1964): The juxtavesical ureter is
dissected and a submucosal groove is created extending
laterally from the ureteral hiatus along the course of the
ureter. The ureter is placed in the groove and the detrusor is
closed over the ureter [22–24].
Advantages: This technique does not require bladder
opening or ureteral stent placement.
Disadvantages: There is an increased risk for pelvic
nerve damage and urinary retention, especially for bilateral
procedures, and is not performed within the first year of
life.
Fig. 1 International classifica-
tion of Vesicoureteral reflux
[11], used with permission
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Politano-Leadbetter (1958): The ureter is mobilized intra-
vesically and then brought through a new muscular hiatus
located superior and lateral to the original mucosal orifice
[25, 26].
Advantages: This technique enables creation of a longer
tunnel, which is useful in higher grades of reflux.
Disadvantages: In addition to postoperative hematuria,
patients are at risk for ureteral kinking/obstruction and
bowel injury.
Glenn-Anderson (1967): The ureter is advanced distally
through a submucosal tunnel extending inferomedially
towards the bladder neck. A later modification with
proximal incision of the detrusor at the original hiatus
enabled creation of a longer tunnel [27, 28].
Advantages: There is a reduced risk for ureteral kinking/
obstruction with this technique.
Disadvantages: The distal ureteral anastomosis may be
challenging due to proximity to the bladder neck.
Cohen (1975): The ureter is advanced through a
submucosal tunnel across the trigone to the contralateral
Table 1 Open Surgery
The illustrations used in this table are from the references 24, 26, 27, 30, and are used with permission.
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to the contralateral orifice [29, 30].
Advantages: This technique enables creation of a longer
tunnel length and avoids ureteral kinking.
Disadvantages: Retrograde catheterization is difficult
following repair.
Laparoscopic repair
Laparoscopic approaches to reflux repair were first de-
scribed in the mid-1990s [31, 32]. Intravesical and extra-
vesical approaches have been described with the latter
being more common. Theoretical advantages include
decreased hospital stay, decreased postoperative pain/anal-
gesic requirement, smaller incisions, and faster recovery.
Early results demonstrate similar efficacy to open proce-
dures, with success rates of 88–100%, but technical
difficulty, longer operative times, and higher rate of
complications including ureteral injury/obstruction, urine
leak, and fistula, have precluded widespread adoption [33].
Other minimally invasive techniques including pneumo-
vesiscopic and robotic-assisted approached have been
described, however, further studies are required to demon-
strate the benefit over standard open repairs.
Endoscopic repair
Endoscopic repairs prevent reflux by injection of a bulking
agent to allow elevation and coaptation of the ureteral
orifice and ureteral wall [34]. Benefits include outpatient
surgery, lower cost, and decreased patient morbidity.
Various methods of injection (sub-ureteral and intra-
ureteral) and injectable materials have been described. In
a systematic meta-analysis evaluating endoscopic treatment
of pediatric VUR, the estimated success rate for endoscopic
therapy after a single injection was 83.0% (95% CI 69.1,
91.4) [1]. Presence of bladder and bowel dysfunction does
not affect the cure rate for open surgical procedures but
does for endoscopic procedures.
The ideal injectable material should have the following
qualities:
– Durable, effective, safe
– Inert, easily injectable, stable with time
– Must not extrude or migrate
– Biocompatible, non-antigenic, non-carcinogenic
Initial reports of endoscopic injections were with a
polytetrafluoroethylene (PTFE) paste, however, this sub-
stance was not approved for use in the United States due to
migration to other organ sites. Dextranomer hyaluronic acid
(Dx/HA or Deflux®) was approved by the FDA in 2001 for
the treatment of VUR grades 1–4. Dx/HA copolymer is a
viscous gel consisting of two sugar-based molecules:
Dextranomer (Dx) microspheres suspended in non-animal
hyaluronic acid (HA). In contrast to PTFE, Dx/HA micro-
spheres are larger in size (80–250 µm) and therefore less
likely to embolize or migrate. Other bulking agents include
Macroplastique® (polydimethylsiloxane particles sus-
pended in polyvinylpyrrolidone or PVP carrier gel) and
collagen; the latter is antigenic and may be absorbed.
Sub-ureteral –“ STING”
Endoscopic treatment of VUR was first described by
O’Donnell and Puri in 1984 (Fig. 2). They performed
subureteric Teflon injection (STING) in 13 patients with
reflux. A total of 78% had resolution of reflux after a
single injection [35]. The same group later reported their
experience after treatment of 1,101 ureters. Success rates
following single injection were 100, 93.1, 77.7, and
Fig. 2 STING [34], used with permission
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Most of these patients had grade III or IV reflux. Only
reflux grade and younger patient age were independent
risk factors associated with failure on logistic regression
analysis.
Intraureteral –“ HIT”
In 2004, Kirsch described a modification called the hydro-
distention implantation technique (HIT) (Figs. 3, 4, 5). The
needle is advanced into the ureteral tunnel and Dx/Ha is
injected along the entire length of the detrusor tunnel for
maximal coaptation. A total of 89% of patients undergoing
HIT had resolution of reflux versus 79% undergoing
standard STING [37]. HIT was further modified to include
two intraureteral injections (proximal and distal), for total
ureteral tunnel coaptation. The goals of "double HIT" are to
create a "mountain range appearance" of the ureteral tunnel
and eliminate hydrodistention [38]. Success rates ranged
from 70 to 95%.
Subsequent multivariate analyses have failed to demon-
strate a significant difference in outcomes between STING
and HIT techniques [39–41]. Other factors that have been
evaluated as potential predictors of endoscopic injection
Fig. 3 Double HIT [34], used with permission
Fig. 4 Injection sites bulking material is injected at sites 1 and 2 for
the double HIT method, and site 3 for the STING method [34], used
with permission
Fig. 5 Morphology of injected mound
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anatomic abnormalities, voiding dysfunction, injected vol-
ume, mound morphology/location, surgeon factors/experi-
ence, and duration of follow-up [42, 43]. While patients
with higher pre-operative reflux grade and voiding dys-
function have lower success rates with endoscopic injec-
tion, injection technique and volume do not appear to be
significant predictors of success.
Outcomes
Resolution of reflux
Short-term results
There is considerable evidence including level 1 and 2 data,
supporting the use of endoscopic injection in the treatment
of VUR grades 1–4 in pediatric patients [44–46]. These
studies demonstrate single-injection, per-ureter reflux reso-
lution rates ranging from 52 to 77% (Table 2). In one meta-
analysis [45], individual study success ranged from 44 to
92%. Not surprisingly, 87% of this variability was related to
between-study variability. There are several potential
explanations for these discrepancies. First, definitions of
"success" differ among authors. In the US, treatment
success is typically defined as grade 0 or no reflux, while
other authors have defined success as grade 2 or less reflux.
Second, there is variability among patient populations since
not all studies include patients with functional/anatomic
bladder abnormalities such as voiding dysfunction, neuro-
pathic bladder, duplicated systems, and ureteroceles. Third,
differences in injection technique and bulking agents have
evolved over time and may account for some variability in
outcomes. These discrepancies highlight the need for more
standardized study designs and outcome reporting in the
future. Despite these limitations, the evidence indicates that
endoscopic injection is effective for the treatment of most
Table 2 Outcomes of single endoscopic injection with DHA
LOE Study Year Patients/
ureters
Pre-op
VUR
grade
Success
rate
a
Last
VCUG
years
after
Tx
Patients/
ureters w/late
VCUG
Recurrent VUR
No ureters (%)
b
Febrile UTI No
patients (%)
NF-UTI No
patients (%)
1b Läckgren [47] 2001 221/334 3–5 54%* 2–5 49/77 13 (17%) G3-4 8/221 (3.5%) 11/221 (4.8%)
20 (26%) G2-4
1b Oswald [48] 2002 38/56 2–4 71.4%* 1 22/32 10 (31.2%) ––
62.5%
**
2b Kirsch [60] 2003 180
ζ/292 1–4 72%** –– – – –
1a Elder
c [44], [60] 2006 5,527/
8,101
1–5 75.7%
***
–– – 0.75% 6%
2b Lee [49] 2009 219/337 1–5 73%** 1 −/150 39 (26%) ––
2b Chertin [54] 2009 507/696
PTFE or
DHA
1–5 68%** 1–12 11/- 8 (72.7%)
ψ
(3 DHA)
11/507 (2.2%)
(3 DHA)
28/507 (5.6%)
2b Hsieh [50] 2010 166/265 1–5 86.4%
**
1 44/- – 0/44 (0%) 11/44 (25%)
1b Holmdahl [46] 2010 66/82 3–4 54.5%* 2 52/63 30 (47.6%) G2-4 14/66 (21%) –
Brandström [51] 52%** 66/- 13 (20%)
ψ G3-4
2a Routh [45] 2010 −/7,303 1–5 77%
***
–– – – –
aAll reported as per-ureter success rate following single injection except Läckgren and Kirsch (per-patient success rate)
bAll reported as per ureter recurrence rate except Chertin and Holmdahl (per-patient recurrence rate)
cAnalysis includes studies using non-DHA bulking agents
LOE Level of evidence; NF Non-febrile
*Success ≤ grade 1 reflux
**Success = no reflux
***Success varies with each author’s definition
ψPer-patient recurrence rate
ζ134 patients had 3-month follow-up and were included in analysis
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reflux grade and structural/functional bladder abnormalities
in ultimate treatment success.
Long-term results
Due to recent reports of recurrent reflux following successful
endoscopic injection, increased attention has been focused on
treatment durability. Most patients who receive endoscopic
injection are evaluated with a post-operative VCUG at
3 months. Few patients will undergo additional VCUG unless
clinically indicated by febrile UTI. Thus, the long-term
efficacy of endoscopic injection is not known.
Several groups have published long-term results after
endoscopic injection [47–51]. The time of last post-operative
VCUG ranged from 1 to 12 years (Table 2). Recurrent reflux
occurred in 17 to 47.6% of ureters, with a median of 26%.
The incidence of febrile and non-febrile UTI following
injection ranged from 0–21% and 5.6–25%, respectively.
With the exception of the Swedish trial, thesewerelowerthan
previously published UTI rates following open surgical
correction ofreflux (8% pyelonephritis, 32-39% cystitis) [52].
Several factors likely play a role in the variability of
reported outcomes. These include small patient numbers,
presence of varying degrees of anatomic/functional bladder
abnormalities, and differences in injection techniques,
definitions of reflux recurrence, and methods of calculating
recurrence. Most studies defined recurrent reflux as grade 2
or higher reflux and limited repeat VCUGs to patients
diagnosed with febrile UTI. Thus, the true rate of reflux
recurrence cannot be measured. Of note, the Swedish trial
[46, 51] was the only prospective randomized trial
evaluating VUR status and recurrent UTI. In this study,
20% of patients developed recurrent dilating reflux follow-
ing endoscopic injection at 2-year VCUG. A total of 21%
of patients in the endoscopic treatment arm had one or more
recurrent febrile UTI following injection. The incidence of
recurrent UTI was 2–3 times higher among girls in the
surveillance (57%) versus antibiotic prophylaxis (19%) and
endoscopic (23%) arms. Further analysis showed that
compared to controls, both endoscopic treatment and
antibiotic prophylaxis significantly decreased the rate of
recurrent febrile UTI in girls with grade 3–4 VUR. There
was no benefit from treatment in boys greater than 1 year of
age with dilating VUR.
Taken together, the data suggest that a significant fraction
of patients with successful endoscopic injection on initial
VCUG may ultimately develop recurrent reflux. In addition,
up to 20% of patients treated with endoscopic injection may
develop recurrent febrile UTI, with girls at greater risk than
boys. For these reasons, longer follow-up and repeat VCUG
may be warranted to evaluate for late failures.
Renal damage
Two studies [53, 54] have evaluated the development of
new renal damage, which includes both renal deterioration
and scarring, following treatment of reflux with endoscopic
injection. Patients were evaluated with pre- and post-
operative DMSA scan; those with functional/anatomic
bladder abnormalities were excluded. Pre-operative renal
scarring was present in 78% and 61% of renal units and
patients, respectively. New, post-operative renal deteriora-
tion and scarring developed in 7.5% of renal units and 9.1%
of patients, respectively. In the Swedish trial, there was no
statistical difference in renal status deterioration (new renal
scar of >3% decreased relative function) among surveil-
lance (18%), endoscopic (12%), and antibiotic prophylaxis
(6%) groups. Renal damage was strongly associated with
recurrent febrile UTI and new renal scarring was highest in
girls in the surveillance arm with dilating reflux at study
entry. These data demonstrate that new renal damage
following endoscopic injection is relatively uncommon.
Nonetheless, it may still occur, particularly in female
patients presenting with febrile UTI. Given this risk,
prompt evaluation and treatment of febrile UTI should be
initiated in patients who have been previously treated with
endoscopic injection.
Discussion
Vesicoureteral reflux is the most common uropathy in
children. Although spontaneous resolution in primary
reflux is common, surgical intervention may be necessary
in patients with persistent reflux, recurrent pyelonephritis,
renal scarring, or breakthrough febrile UTI. Both open and
endoscopic approaches to reflux correction are highly
successful and reduce the occurrence of febrile UTI. In
comparison, no difference has been shown in the incidence
of new renal damage following open surgical correction or
antibiotic prophylaxis (5-14% vs. 6-12%, respectively). In
addition, the incidence of new renal damage after endo-
scopic treatment appears to be comparable (9-12%) to open
correction; however, there has been no study directly
comparing outcomes of open and endoscopic correction of
reflux.
Decisions for surgical repair and type of repair are
individualized. The choice of surgical modality is based on
reflux grade, treatment efficacy/morbidity, and family
preference. With the advent of Dx/HA copolymer, endo-
scopic therapy has become the first-line therapy for many
patients with reflux. In contrast to antibiotic prophylaxis,
endoscopic injection offers an immediate cure with minimal
adverse effects and is independent of patient compliance.
558 Pediatr Nephrol (2012) 27:551–561Compared to open repair, endoscopic therapy is associated
with decreased patient morbidity and possibly lower costs.
Studies evaluating the cost-effectiveness of endoscopic
treatment suggest that it may be superior to open ureteral
reimplantation in some settings; however, it is unclear if
this advantage remains in cases of high-grade, bilateral, and
recurrent reflux [55, 56]. A recent study on the treatment
patterns of reflux showed that 80% of parents of patients
with moderately severe VUR chose endoscopic injection
when given information on each of the treatment options
[57]. Both the opinion of the pediatric urologist and the
individual hospital at which the patient seeks treatment
influenced the procedure performed [58, 59].
Given the success of endoscopic therapy, the 2010 AUA
guidelines were revised to include this treatment modality in
the management options for VUR. "It is recommended that
patients receiving CAP with a febrile breakthrough UTI be
considered for open surgical ureteral reimplantation or
endoscopic injection of bulking agents for intervention with
curative intent" [1]. In addition, these guidelines outline
indications for post-operative imaging in patients who have
received definitive treatment for VUR. "With the occurrence
of a febrile UTI following resolution or surgical treatment of
VUR, evaluation for bladder and bowel dysfunction or
recurrent VUR is recommended." Though endoscopic
injection may be successful in most patients with primary
reflux (grades 1–4), it is our opinion that open repair may be
indicated in complex patients with voiding dysfunction,
anatomic abnormalities, or those who have failed prior
endoscopic injections.
Conclusions
Endoscopic injection of dextranomer/hyaluronic acid
(DHA) has emerged as a highly successful, minimally
invasive therapy for VUR. Multiple studies have demon-
strated safety and efficacy of this treatment modality for the
correction of reflux. Success rates are comparable to open
surgery with added benefits of being an outpatient
procedure and minimal associated morbidity. The most
important predictors of success include pre-operative reflux
grade and the absence of functional/anatomic bladder
abnormalities including voiding dysfunction, neuropathic
bladder, duplicated systems, and ureterocele. Given recent
reports of late failures, additional studies are needed to
determine treatment durability. In addition, longer follow-
up and repeat VCUG may be warranted, particularly in
patients with febrile UTI following treatment with Deflux®.
Despite these limitations, endoscopic injection is effective
in most children and should be considered as an option in
the management of persistent VUR.
Summary points
& Children with VUR are more likely to develop acute
pyelonephritis and renal scarring compared to children
without VUR.
& Surgical correction of VUR reduces the occurrence of
febrile UTIs.
& The 2010 AUA guidelines recommend consideration of
surgical (open or endoscopic) correction of VUR in
patients receiving continuous antibiotic prophylaxis
with a febrile breakthrough UTI.
& Pre-operative reflux grade is the single most important
factor affecting the success rate of endoscopic injection.
& Patients with febrile UTI following treatment with
endoscopic injection should be evaluated with VCUG
to rule out recurrent VUR.
Research points
& Multivariate analyses have not shown a significant
difference in outcomes between intraureteral and sub-
ureteral injection techniques.
& Technical factors affecting the success of endoscopic
injection need further refinement.
& Small patient numbers and differences in injection
techniques, study design, patient characteristics, and
definition/calculation of reflux recurrence contribute to
the wide variability in long-term results after endo-
scopic injection.
& Additional studies with standardized outcome reporting
and longer follow-up are needed to evaluate the
durability of endoscopic injection.
& Further studies are needed to evaluate the risk and
clinical significance of renal damage following treat-
ment with endoscopic injection.
Multiple choice questions: answers appear following the
reference list.
1. What is the success rate of endoscopic injection for
treatment of VUR
a. 30-40%
b. 50-60%
c. 70-80%
d. 90-95%
2. What is the risk of renal scarring following first UTI
a. 5%
b. 10%
c. 15%
d. 25%
Pediatr Nephrol (2012) 27:551–561 5593. All of the following are recommendations based on the
2010 AUA guidelines for the treatment of VUR,
except:
a. A VCUG should be performed following a febrile
UTI in a child with prior successful endoscopic
treatment.
b. Surgical correction is recommended for patients on
antibiotic prophylaxis with febrile break-through
UTI.
c. Either endoscopic or open repair of VUR are
acceptable options for surgical correction.
d. Endoscopic injection is effective for the treatment
of grade 5 VUR.
4. The only factor which has been demonstrated to
significantly influence DHA injection success rate is:
a. Surgeon experience
b. Pre-operative VUR grade
c. Injection volume
d. Conflict of interest
5. Which of the following is not true of endoscopic
treatment of reflux:
a. Entails injection of a bulking agent, allowing
coaptation of the ureteral orifice.
b. Sub-ureteral and intraureteral injection techniques
have been described.
c. Presence of bladder and bowel dysfunction does
not affect the cure rate.
d. Benefits include outpatient surgery and decreased
patient morbidity.
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